PMGC Holdings Business Summary

PMGC Holdings Inc. (NASDAQ: ELAB), formerly Elevai Labs Inc., operates as a diversified holding company utilizing a "permanent capital" model to acquire and scale cash-flowing assets across the biopharmaceutical, medical aesthetics, and precision manufacturing sectors. The company generates revenue through a multi-pronged approach: direct-to-physician sales of its proprietary exosome-based skincare products via Elevai Skincare, contract manufacturing and engineering services through its precision machining subsidiaries (AGA Precision Systems and SVM Machining), and strategic biopharmaceutical R&D focused on muscle preservation and metabolic health (NorthStrive Biosciences). Its primary business segments include Corporate/Treasury, Biosciences, and Precision Engineering, with recent expansion into aerospace and defense manufacturing to stabilize the high-volatility R&D pipeline with consistent industrial cash flows. PMGC competes directly with small-cap pharmaceutical and aesthetic firms such as Ernexa Therapeutics (ERNA), China SXT Pharmaceuticals (SXTC), and Avalon GloboCare (ALBT), positioning itself as a vertically integrated holding entity that bridges the gap between clinical-stage biotech and high-precision industrial manufacturing. Leadership is spearheaded by Graydon Bensler, CFA, who serves as the parent company’s Chief Executive Officer and Chief Financial Officer. Bensler, a capital markets specialist and founder of GB Capital Ltd., brings extensive expertise in M&A, transaction execution, and public company readiness. The company was co-founded by Dr. Jordan R. Plews, a Stanford-trained biochemical engineer and former Pfizer researcher who currently serves as CEO of the Skincare and Biosciences subsidiaries, and Braeden Lichti, who remains the Non-Executive Chairman of the Board. The executive team is supported by a Scientific Advisory Board featuring prominent researchers like Dr. Orian Shirihai and Dr. Roger Fielding, alongside independent directors Jeffrey Parry and George Kovalyov. This leadership structure combines deep technical pedigree in regenerative medicine with institutional capital markets experience to drive the company’s aggressive roll-up strategy and clinical development of its lead probiotic candidates, EL-22 and EL-32.